Please login to the form below

Not currently logged in
Email:
Password:

Amgen biosimilar matches AbbVie's Humira in psoriasis trial

ABP 501 set to compete with world’s biggest-selling drug
Amgen flag

Amgen is on track to launch a biosimilar competitor to AbbVie's Humira - the biggest-selling pharmaceutical product in the world - after positive data in a phase III trial.

The biotech major said that in the first of two late-stage studies, its ABP 501 biosimilar was equivalent to Humira (adalimumab) in terms of its efficacy and safety in patients with moderate-to-severe plaque psoriasis after 16 weeks' treatment. The drug also matched its rival in terms of its tendency to stimulate an immune response in the patient, which can reduce the effectiveness of antibody treatments.

If the results of the second phase III trial echo the first, Amgen could be in a position to compete directly with Humira when it loses patent protection, due in 2016 in the US and 2018 in Europe.

Other companies such as Boehringer Ingelheim, Novartis unit Sandoz and Coherus are also developing biosimilars of Humira. However, Amgen's biologics expertise and marketing muscle are expected to make it a potent competitor in the marketplace and allow it to grab market share from AbbVie's drug, which racked up a massive $11.5bn in sales last year, according to PMLiVE's Top 50 pharma products list

Top five pharma products for 2013

Product
Company
Revenues for 2013 ($m)
Humira
AbbVie
11,511
Remicade
Johnson & Johnson/Mitsubishi Tanabe/Merck & Co
9,935
Enbrel
Amgen/Pfizer8,897
Seretide/Advair
GSK
8,356
Abilify
BMS/Otsuka
8,031

For AbbVie competition will be a very big deal, as Humira accounts for 60% of its revenues, although because biosimilars are typically priced at a 20%-30% discount to the originator drug they do not generally cause the dramatic reduction in brand sales that occur with generics of small-molecule drugs.

The pharma company is banking on pipeline projects - such as its new combination therapy for hepatitis C - to offset the start of competition to its top product and has also agreed a $55bn deal to acquire rare disease specialist Shire to bolster its portfolio.

The ABP 501 data "further demonstrates [Amgen's] commitment to provide patients with access to high-quality medicines," commented Sean Harper, the biotech's R&D head.

"We look forward to continuing to leverage our experience and expertise in biotechnology to bring biosimilars to patients," he added.

Amgen has set up a big programme in biosimilars, with six drugs in development and the first due to reach the market in 2017, although it is already facing biosimilar competition to its own drugs such as Neupogen (filgrastim) and Epogen (epoetin alfa) in Europe. 

The other biosimilars in its pipeline are thought to include versions of Roche's Avastin (bevacizumab) and Herceptin (trastuzumab), Roche/Biogen Idec's MabThera/Rituxan (rituximab), Johnson & Johnson's Remicade (infliximab), and Bristol-Myers Squibb/Eli Lilly's Erbitux (cetuximab).

All told, the global biosimilars market is expected to grow to around $25bn by the end of the decade as drugs with sales of around $100bn lose patent protection, according to a recent report from Thomson Reuters.

Article by
Phil Taylor

9th October 2014

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics